Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
20.12 USD | -8.50% | -5.87% | +233.67% |
Financials (USD)
Sales 2024 * | 2.14M | Sales 2025 * | - | Capitalization | 782M |
---|---|---|---|---|---|
Net income 2024 * | -66M | Net income 2025 * | -93M | EV / Sales 2024 * | 240 x |
Net cash position 2024 * | 267M | Net cash position 2025 * | 320M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-10.8
x | P/E ratio 2025 * |
-8.81
x | Employees | 50 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.5% |
Latest transcript on Longboard Pharmaceuticals, Inc.
1 day | -8.50% | ||
1 week | -5.87% | ||
Current month | -5.54% | ||
1 month | +9.89% | ||
3 months | +1.87% | ||
6 months | +285.81% | ||
Current year | +233.67% |
Managers | Title | Age | Since |
---|---|---|---|
Kevin Lind
CEO | Chief Executive Officer | 47 | 20-01-02 |
Brandi Roberts
DFI | Director of Finance/CFO | 50 | 20-12-31 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Sekhri
CHM | Chairman | 65 | 20-11-30 |
Director/Board Member | 67 | 20-11-30 | |
Vincent Aurentz
BRD | Director/Board Member | 56 | 20-01-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.41% | 4 M€ | -5.15% | - | |
0.00% | 0 M€ | +3.63% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 20.12 | -8.50% | 156,226 |
24-05-09 | 21.99 | +1.34% | 139,394 |
24-05-08 | 21.7 | -1.56% | 273,545 |
24-05-07 | 22.04 | +7.01% | 316,024 |
24-05-06 | 20.6 | -3.63% | 427,903 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+233.67% | 782M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- LBPH Stock